Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small cell lung carcinoma

BACKGROUND: Osimertinib is recommended for T790M mutation‐positive advanced non‐small cell lung cancer (NSCLC) resistant to first‐ and second‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs). Recently, some reports exist on the real‐world use of osimertinib; howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishikawa, Takayuki, Kasai, Takashi, Okada, Masahiko, Nakachi, Ichiro, Soda, Sayo, Arai, Ryo, Takigami, Ayako, Sata, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113046/
https://www.ncbi.nlm.nih.gov/pubmed/32129931
http://dx.doi.org/10.1111/1759-7714.13378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113046/
https://www.ncbi.nlm.nih.gov/pubmed/32129931
http://dx.doi.org/10.1111/1759-7714.13378

Ejemplares similares